ID Source | ID |
---|---|
PubMed CID | 8589 |
CHEMBL ID | 2104858 |
CHEBI ID | 32069 |
SCHEMBL ID | 41604 |
MeSH ID | M0047229 |
Synonym |
---|
1,4-oxadiazole, 5-[2-(diethylamino)ethyl]-3-(.alpha.-ethylbenzyl)-, citrate (1:1) |
proxazole citrate |
nsc-303872 |
1,4-oxadiazole, 5-[2-(diethylamino)ethyl]-3-(.alpha.-ethylbenzyl)-, citrate |
132-35-4 |
propaxoline |
af 634 |
pirecin |
proxazol citrate |
1,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
nsc303872 |
5-[2-(diethylamino)ethyl]-3-(.alpha.-ethylbenzyl)-1,4-oxadiazole citrate (1:1) |
aerbron |
af-634 |
solacil |
propaxolin |
mls003115794 , |
toness |
einecs 205-059-8 |
5-(2-(diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate |
5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate |
3-alpha-phenylpropyl-5-beta-diethylaminoethyl-1,2,4-oxadiazole citrate |
nsc 303872 |
flou |
n,n-diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine citrate |
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate |
1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate (1:1) |
propaxolin citrate |
proxazole citrate [usan] |
5-(2-(diethylamino)ethyl)-3-(alpha-phenylpropyl)-1,2,4-oxadiazole citrate |
1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, citrate |
propaxoline citrate |
citric acid; n,n-diethyl-2-[3-(1-phenylpropyl)-1,2,4-oxadiazol-5-yl]ethanamine |
1,2, 4-oxadiazole, {5-[2-(diethylamino)ethyl]-3-(.alpha.-ethylbenzyl)-,} citrate (1:1) |
n,n-diethyl-2-(3-(1-phenylpropyl)-1,2,4-oxadiazol-5-yl)ethanamine 2-hydroxy-1,2,3-propanetricarboxylate |
{5-[2-(diethylamino)ethyl]-3-(.alpha.-ethylbenzyl)-1,2,} 4-oxadiazole citrate (1:1) |
1,2, 4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
proxazole citrate(usan) |
1,2,4-oxadiazole, {5-[2-(diethylamino)ethyl]-3-(.alpha.-ethylbenzyl)-,} citrate |
1,2,4-oxadiazole, 5-[2-(diethylamino)ethyl]-3-(.alpha.-ethylbenzyl)-, citrate |
toness (tn) |
D01650 |
proxazole citrate (jan/usan) |
smr001831360 |
unii-yr02ikm54o |
yr02ikm54o , |
tox21_113225 |
dtxsid5048760 , |
dtxcid8028686 |
cas-132-35-4 |
AKOS015994605 |
CHEMBL2104858 |
SCHEMBL41604 |
HS-0015 |
proxazole citrate [mi] |
19248-55-6 |
3-.alpha.-phenylpropyl-5-(.beta.-diethylaminoethyl)-1,2,4-oxadiazole citrate |
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(.alpha.-ethylbenzyl)-, citrate (1:1) |
proxazole citrate [jan] |
3.alpha.-phenylpropyl-5.beta.-diethylaminoethyl-1,2,4-oxadiazol citrate |
proxazole citrate [who-dd] |
n,n-diethyl-2-(3-(1-phenylpropyl)-1,2,4-oxadiazol-5-yl)ethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate |
CHEBI:32069 |
n,n-diethyl-2-(3-(1-phenylpropyl)-1,2,4-oxadiazol-5-yl)ethanamine 2-hydroxypropane-1,2,3-tricarboxylate |
Q27294669 |
n,n-diethyl-2-[3-(1-phenylpropyl)-1,2,4-oxadiazol-5-yl]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid |
5-[2-(diethylammonio)ethyl]-3-(1-phenylpropyl)-1,2,4-oxadiazolediyliumcitrate |
n,n-diethyl-2-(3-(1-phenylpropyl)-1,2,4-oxadiazol-5-yl)ethanamine2-hydroxypropane-1,2,3-tricarboxylate |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Class | Description |
---|---|
carbonyl compound | Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 15.8489 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.6822 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 19.9526 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 25.1189 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (52.12) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |